EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, REGN:

29 Aug 2025
LAST:

580.7

CHANGE:
 1.09		OPEN:
577.2		HIGH:
581.2		ASK:
311.4		VOLUME:
574.3K
CHG(%):
0.19		PREV:
579.6		LOW:
575.9		BID:
25.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
29 Aug 25577.2581.2575.9580.7574.3K
28 Aug 25586.4591.0575.0579.6616.6K
27 Aug 25591.9597.0585.5587.0584.1K
26 Aug 25573.0588.1567.1587.71.61M
25 Aug 25591.1594.9572.3572.4881K
22 Aug 25602.4610.5585.5589.51.44M
21 Aug 25586.9605.2585.1598.21.01M
20 Aug 25572.3596.9570.4591.01.3M
19 Aug 25575.3581.7570.8571.8854.7K
18 Aug 25582.1585.0573.8573.9769.3K

COMPANY PROFILE

Name:
About:Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Sector:Healthcare
Industry:Biotechnology
Address:777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Website:https://www.regeneron.com
CUSIP:75886F107
CIK:0000872589
ISIN:US75886F1075
FIGI:BBG000C734W3
LEI:549300RCBFWIRX3HYQ56

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:14.41
DivYield:0.00
Div/Share:1.76
PtB:2.02
PtS:4.26
EBITDA:4.467B
Shares:104.17M
Market Cap:60.492B

TECHNICAL INDICATORS

MA5:581.46
MA10:583.16
MA20:573.07
MA50:556.60
MA100:557.72
MA200:628.73
STO9:23.07
STO14:44.80
RSI14:64.52
WPR14:-41.97
MTM14:24.15
ROC14:0.04
ATR:16.56
Week High:610.45
Week Low:567.08
Month High:610.45
Month Low:541.61
Year High:1,210.97
Year Low:476.49
Volatility:11.58

RECENT DIVIDENDS

Date Amount
18 Aug 2025$0.88
20 May 2025$0.88
20 Feb 2025$0.88